<DOC>
	<DOCNO>NCT01878422</DOCNO>
	<brief_summary>Study Design : This pragmatic study management strategy patient metastatic colorectal cancer ( CRC ) candidate CT , independently previous adjuvant therapy receive . The aim study define role new target molecule combination CT first- second line treatment . First line study : Eligible patient randomize either treatment : Arm A : FOLFIRI FOLFOX + Bevacizumab , cycle repeat every 2 week - BEVACIZUMAB : Day 1,1st cycle 5 mg/kg IV infusion 90 min Day 1 , 2nd cycle well tolerate , 5 mg/kg IV infusion 60 min Day 1 , 3rd cycle subsequent cycle well tolerate , 5 mg/kg IV infusion 30 min 5-Fluorouracile ( FU ) bolus - FOLFIRI Day 1 : Irinotecan 180 mg/m2 IV infusion 30-90 min Day 1,2 : L-Folinic acid 100 mg/m2 IV infusion 2 hour 5-Fluorouracil 400 mg/m2 bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion 22 hour - FOLFOX Day 1 : Oxaliplatin 85 mg/m2 IV infusion 2hours Day 1,2 : L-Folinic acid 100 mg/m2 IV infusion 2 hour 5-Fluorouracil 400 mg/m2 bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion 22 hour Arm B : FOLFIRI FOLFOX , cycle repeat every 2 week If FOLFIRI : FOLFIRI specify arm A without Bevacizumab If FOLFOX : FOLFOX specify arm A without Bevacizumab Duration Therapy For arm , CT repeat progressive disease ( PD ) unacceptable toxicity occur . If unacceptable CT-related toxicity occur ARM A , absence PD patient stop CT continue bevacizumab 5 mg/kg 30-min infusion every 2 week progression intolerable toxicity occur . Second line - divide two different study ( 2A 2B ) : Study 2A : Patients arm A Kras Wild Type randomize : - Arm C : FOLFIRI FOLFOX ( CT schedule receive 1st line trial , define arm B ) - Arm D : FOLFIRI FOLFOX ( CT schedule receive 1st line trial , describe arm B ) plus CETUXIMAB CETUXIMAB 1st cycle Day 1 400 mg/m2 infusion 120 min 2 hr CT infusion 1st cycle Day 8 subsequent cycle 250 mg/m2 infusion 60 min 1 hr CT infusion Patients arm A Kras Mutant treat accord arm C. Study 2B : Patients arm B Kras Wild Type randomize : - Arm E : FOLFIRI FOLFOX ( CT schedule receive 1st line trial , define arm B ) plus BEVACIZUMAB - Arm F : FOLFIRI FOLFOX ( CT schedule receive first-line trial , define arm B ) plus BEVACIZUMAB CETUXIMAB ; cycle repeat every 2 week , whilst cetuximab administer weekly . - BEVACIZUMAB 2nd day 1st cycle 5 mg/kg IV infusion 90 min 2nd day 2 nd cycle well tolerate , 5 mg/kg IV infusion 60 min 2nd day 3 rd cycle subsequent cycle well tolerate , 5 mg/kg IV infusion 30 min end 5-FU bolus 2nd day - CETUXIMAB 1st cycle Day 1 400 mg/m2 infusion 120 min 2 hr CT infusion 1st cycle Day 8 subsequent cycle 250 mg/m2 infusion 60 min 1 hr CT infusion If cetuximab stop reason specify protocol , bevacizumab administer defined arm A 1st line study Patients arm B Kras Mutant treat accord arm E. Objectives study The primary objective 1st line study determine whether addition bevacizumab poly-chemotherapy ( polyCT ) regimen ( FOLFIRI FOLFOX ) improve efficacy term progression-free survival ( PFS ) . The secondary objective 1st line study determine Overall Response Rate ( ORR ) safety profile treatment administer . The primary objective 2nd line study determine , separately study , whether addition cetuximab polyCT scheme ( FOLFOX FOLFIRI ) , polyCT scheme plus bevacizumab , improve efficacy term PFS.The secondary objective 2nd line study determine ORR , overall survival ( OS ) safety profile treatment administer .</brief_summary>
	<brief_title>Sequential Treatment Strategy Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1 . Histologically cytologically confirm untreated metastatic locally advanced , non resectable CRC ; previous adjuvant chemotherapy CRC neoadjuvant/adjuvant chemoradiotherapy rectal cancer permit must complete least 6 month prior enrolment ; 2 . Resected CRC patient develop metastasis require separate histological cytological confirmation unless &gt; 5 yr elapse primary surgery primary tumor stage I ; 3 . Evaluation Kras status primary tumor metastases 4 . Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST criterion ) 5 . Age ≥ 18 year &lt; 70 year Performance Status ( ECOG ) ≤ 2 age &gt; 70 year ECOG ≤ 1 ; 6 . Estimated life expectancy least 12 week ; 7 . Adequate hematological , hepatic renal function , follow : hemoglobin ≥ 9 g/dl , absolute neutrophil count ≥1,500/μL , platelets ≥100,000/μL , total bilirubin ≤1.5 x upper limit normal ( ULN ) , alkaline phosphatase , aspartate aminotransferase ( AST ( SGOT ) ) alanine aminotransferase ( ALT ( SGPT ) ) ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) , serum creatinine ≤ 1.5 x ULN calculate creatinine clearance &gt; 50 mL/min ( calculate basis Standard Cockcroft Gault Formula , urinary excretion ( protein &gt; 30 mg/dL +1 , patient must ≤ 1 g protein/24 hour ) 8 . Either international normalized ratio ( INR ) activate partial thromboplastin time ( APTT ) &lt; 1.5 x ULN Ddimer within normal range ( abnormal , thromboembolic event must exclude ) ; 9 . Negative pregnancy test 7 day randomization ; test pregnancy omit woman without reproductive potential ( e.g . : postmenopausal woman , i.e . amenorrhoea ≥2 year previous hysterectomy bilateral ovariectomy ) . Women childbearing potential men must agree use adequate contraception time randomization duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician coordinating centre ( CC ) immediately ; woman lactation period must exclude ; 10 . Ability understand willingness sign write informed consent document . 1 . Prior treatment cetuximab , bevacizumab anti Epidermal Growth Factor Receptor ( antiEGFR ) antiangiogenesis agent ; 2 . Prior chemotherapy immunotherapy metastatic advanced disease ; 3 . Participation another clinical trial investigational agent ≤ 30 day prior study randomization ; 4 . Contraindications hypersensitivity study drug ; 5 . Treatment concomitant antineoplastic drug ; 6 . Other know malignant neoplastic disease patient 's medical history diseasefree interval le 5 year ( except previously treat basal cell carcinoma situ carcinoma uterine cervix ) ; 7 . Symptomatic brain central nervous system metastases clinically relevant central nervous disease ( example : primary brain tumor , uncontrolled convulsion medical therapy , carcinomatous meningitis ) ; 8 . Grade &gt; 1 peripheral neuropathy ( defined National Cancer Institute Common Toxicity Criteria Adverse Effects ( NCI CTCAE ) v3.0 ) ; 9 . Clinically significant ( i.e . active ) cardiovascular disease e.g . cerebrovascular accident ≤ 6 month prior randomization ) , myocardial infarction ( ≤ 1 year prior randomization ) , uncontrolled hypertension whilst receive chronic medication , unstable angina , New York Heart Association ( NYHA ) grade II congestive heart failure , serious cardiac arrhythmia require medication ; 10 . Malabsorption syndrome lack physical integrity gastrointestinal tract . Diverticulitis . Patients colostomy ileostomy may enter investigator 's discretion . History tracheaoesophageal fistula type fistula ( e.g . abdominal ) , gastrointestinal perforation , intraabdominal abscess ; 11 . Interstitial pneumonia extensive symptomatic fibrosis lung ; 12 . Serious , nonhealing wound , ulcer , bone fracture ; significant traumatic injury 4 week prior enrolment ( complete recover must occur ) ; 13 . Major surgery ( e.g . laparotomy ) 4 week prior study randomization ; 14 . Minor surgery 2 week prior study randomization . Insertion central vascular access device chemotherapy infusion must do least 2 day prior start treatment . Patients randomize recover surgery related toxicity ; 15 . Bleeding diathesis coagulopathy ; 16 . Pulmonary embolism arterial thromboembolism ; 17 . Deep vein thrombosis significant thromboembolic event ; 18 . Clinically significant peripheral vascular disease ; 19 . Previous organ transplantation require immunosuppressive therapy ; 20 . Need chronic oral steroid use ( ≥10 mg/day methylprednisolone equivalent ) treatment nonmalignant condition intermittent prophylactic use antiemetic inhale steroid use ; 21 . Chronic use aspirin ( &gt; 325 mg/day ) non steroidal antiinflammatory agent ( know inhibit platelet function dos use treat chronic inflammatory disease ) ; 22 . In treatment antiplatelets agent ( i.e clopidogrel &gt; 75 mg/day , ticlopidine , dipyridamole ) ; 23 . Undergoing treatment sorivudine chemicallyrelated analogue ( brivudine ) ; 24 . Fulldose oral parenteral anticoagulant thrombolytic treatment therapeutic purpose ≤10 day prior study randomization ; 25 . Geographic inaccessibility ; 26 . Any radiation therapy complete ≤ 4 week prior study randomization . If radiate lesion/s is/are site disease , it/they show progression radiotherapeutic procedure , patient become eligible study ; 27 . Previous embolization thermoablation metastases ≤ 30 day prior study randomization . If lesion site disease , show progression embolization thermoablation procedure , patient become eligible study ; 28 . Laboratory abnormality medical psychiatric disorder would interfere informed consent compliance , could indicate contraindication patient enrolment study ( also know dihydropyrimidine dehydrogenase deficit ) ; 29 . HIVpositivity , whether symptomatic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>